Survodutide Powder


Product Description

Product Introduction: Survodutide Powder

Introduction:

Survodutide is an investigational peptide that acts as a dual glucagon/GLP-1 receptor agonist. Unlike other dual GLP-1/glucagon agonists, it is a glucagon analog, not an oxyntomodulin analog.

img_20170602_140941.jpg

WHY CHOOSE US

PROFESSIONAL TEAM

Professional R&D team, a variety of new products have become the industry's hottest products

QUALITY CONTROL

Professional quality management team, quality assurance, complete certificates.

ADVANCED PRODUCTION EQUIPMENT

Cutting-edge production equipment. guarantee of quality and production capacity.

RICH EXPERIENCE

Rich production experience,with freeze-drying temperature curves of 1000+ products, to ensure the taste

and flavor of the products.

Specifications:

ParameterSpecification
AppearanceWhite powder
Purity≥ 99%
Molecular Weight243.22 g/mol

What is Survodutide :


Survodutide is a novel peptide-based drug that has shown promise in the treatment of chronic obstructive pulmonary disease (COPD).


Here are some key points about Survodutide:

1.Mechanism of Action: Survodutide acts as a dual inhibitor of both CXCR2 (C-X-C chemokine receptor type 2) and formyl peptide receptor 2 (FPR2).

2.Clinical Trials: Survodutide has undergone clinical trials to assess its safety and efficacy in COPD patients.

3.Development Status: As of my last update, Survodutide was in the late stages of clinical development. It represents a new approach to treating COPD by targeting specific inflammatory pathways.

4.Potential Benefits: If approved, Survodutide could offer an additional treatment option for COPD patients who do not respond well to existing therapies or who experience frequent exacerbations despite treatment.

Please note that developments in medical research can occur rapidly, so for the most current information on Survodutide, it's advisable to consult recent scientific literature or trusted medical sources.

Function:

Survodutide, a novel peptide-based drug primarily targeted for the treatment of chronic obstructive pulmonary disease (COPD), possesses several functional properties that distinguish it in therapeutic potential:

1.Dual Receptor Inhibition: Survodutide acts as a dual inhibitor of CXCR2 (C-X-C chemokine receptor type 2) and FPR2 (formyl peptide receptor 2).

These receptors play crucial roles in the recruitment and activation of inflammatory cells, particularly neutrophils, which are central to the inflammatory response in COPD.

By targeting these receptors, Survodutide aims to reduce inflammation in the lungs, thereby potentially improving lung function and reducing exacerbations associated with COPD.

2.Anti-inflammatory Activity: The inhibition of CXCR2 and FPR2 by Survodutide leads to decreased migration and activation of neutrophils and other inflammatory cells into the lung tissue.

This anti-inflammatory effect is pivotal in managing the chronic inflammation characteristic of COPD, which contributes to disease progression and exacerbations.

3.Potential for Disease Modification: Beyond symptom management, Survodutide holds promise in potentially modifying the disease course of COPD. By mitigating chronic inflammation and its detrimental effects on lung tissue, it aims to slow down disease progression and preserve lung function over time.

4.Inhaled Delivery: Survodutide is administered via inhalation, allowing direct delivery to the lungs where the inflammatory processes in COPD are predominantly localized. This targeted delivery method enhances the drug's efficacy while potentially minimizing systemic side effects.

5.Clinical Efficacy: Clinical trials of Survodutide have demonstrated promising results in terms of reducing exacerbations, improving lung function (such as FEV1), and enhancing overall quality of life in COPD patients. These outcomes underscore its potential as a valuable addition to the current therapeutic options available for COPD management.

6.Safety Profile: As with any new drug, the safety profile of Survodutide is closely monitored during clinical trials.

Preliminary data suggest that it has been well-tolerated in patients, with manageable side effects observed thus far.

In summary, Survodutide's functional properties revolve around its targeted inhibition of key inflammatory pathways in COPD, potentially leading to significant clinical benefits in terms of symptom control, disease modification, and overall patient outcomes.

PACKING AND SHIPPING

< 1kg---Package: Alu-bag;

<10 KG/Al-Tin---Package: 2 pcs Alu-tin with box;

<25 KG--- Package: Drum (53*36*37cm)=0.07CBM N.G.:25KG, W.G.:28KG

Transportation can be selected based on the weight of the goods and customer needs, which can be TNT, FEDEX, DHL, UPS, EMS. For large orders, they will generally be delivered by air or sea freight.

packing.png

CERTIFICATE SHOW

Our company takes creating high-quality and healthy products as our mission, ensuring product quality as our principle, and has passed ISO9001 quality management system certification, halal and Jewish certification. The company has been constantly striving and has been awarded the high-tech enterprise certificate for many consecutive years.

certificate.png

OUR FACTORY

Jiubaiyuan is a plant extract manufacturer with over 20 years of professional experience. For many years, we have been specializing in the research and production of  Survodutide Powder  . The  Survodutide Powder  produced using unique technology has excellent quality, reasonable price, and supports third-party professional institutions for testing. The application fields include beverage, food, cosmetics, dietary supplements, and other industries. Please contact us for more details!

factory.png

OEM SERVICE

Our company provides services for OEM (Unique Hardware Maker) and ODM(Unique Plan Producer). Our product expert team can customize exclusive products according to customer needs and provide solutions to solve product problems.

OEM3.jpg